Yunu key facts
as of Oct 2026- Developer of a clinical trial imaging platform designed to streamline oncology trials by improving speed, accuracy, and regulatory compliance.
- Yunu is valued at approximately $45.0M as of Oct 2026 (last reported valuation).
- It has raised $14.3M; the latest was Early Stage VC ($11.3M) in Apr 2025.
- Notable investors include Spring Mountain Capital, First Analysis.
- Status: Privately Held (backing).
Yunu's last reported valuation, Apr 2025. Nothing priced has surfaced since.
- ·Watch Yunu: the Monday email on marks, rounds and moves
Yunu funding rounds
No funding rounds for Yunu are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Yunu
2Yunu valuation
Yunu's last reported valuation was $45 million in Apr 2025. No priced round, secondary trade or fund mark has surfaced since.
Yunu investors
2 investors are on record for Yunu, including Spring Mountain Capital and First Analysis.
About Yunu
Developer of a clinical trial imaging platform designed to streamline oncology trials by improving speed, accuracy, and regulatory compliance. The company's platform offers automated workflows, real-time dashboards, protocol-guided imaging assessments, centralized data management, and integrated quality control, enabling sponsors, CROs, and cancer centers to conduct trials efficiently, reduce manual workload, ensure compliance, and quality imaging data.
- Sector
- Healthcare
- HQ
- Cary, NC, United States
- Founded
- 2022
- Employees
- 43
- Website
- yunu.io/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.